Navigation Links
National Institute on Drug Abuse Awards SRI International Contract to Test Safety of Medications for Treatment of Substance Abuse
Date:11/5/2013

MENLO PARK, Calif., Nov. 5, 2013 /PRNewswire/ -- SRI International has been awarded a five-year contract valued up to $9.75 million from the National Institute on Drug Abuse (NIDA) to conduct preclinical safety studies of potential new medications to treat substance abuse. SRI researchers will study potential drug-drug interactions between new treatment therapies and common drugs of abuse to assess potential adverse reactions.

According to the Substance Abuse and Mental Health Services Administration (an agency within the U.S. Department of Health and Human Services), an estimated 22.5 million Americans aged 12 or older—or 8.7 percent of the population—had used an illicit drug or abused a psychotherapeutic medication (such as a pain reliever, stimulant, or tranquilizer) in the past month at the time of a survey in 2011.

"It is important to know early on in the drug development process whether there is potential for a novel drug, when taken in concert with a drug of abuse such as cocaine or morphine, to cause side effects from overdosing, including seizures or other problems," said Howard Stock, Ph.D., senior toxicologist at SRI Biosciences and principal investigator of the project. "We hope that our research will improve people's lives and help those who are suffering from drug addiction."

As part of SRI's contract, NIDA will first identify compounds that may be potential therapeutics. Then SRI researchers will work with NIDA to design and execute preclinical studies to assess the safety of these compounds, both individually and in combination with known drugs of abuse.  In the process, SRI researchers will test compounds at various stages of drug development with the goal of advancing promising discoveries into clinical trials.

"SRI currently performs preclinical drug development under contracts with several other NIH institutes," said Jon Mirsalis, Ph.D., D.A.B.T., managing director of SRI's Biosciences Division. "Applying our expertise to the problems of drug abuse treatment will support NIDA's important mission and SRI's commitment to address global health issues."

This project has been funded in whole with Federal funds from the National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services under Contract No. HHSN271201300035C / NIDA Reference No. N01DA-13-8911.

About SRI's Biosciences Division
SRI Biosciences carries out basic research, drug discovery, and drug development. SRI has all of the resources necessary to take R&D from initial discoveries to clinical trials. SRI's product pipeline has yielded marketed drugs, therapeutics currently in human testing, and additional programs at earlier stages. SRI Biosciences offers a wide range of contract research organization (CRO) services, helping government and industry clients and partners advance drugs and other biomedical products toward commercialization. SRI is also working to create the next generation of technologies in areas such as diagnostics, drug delivery, medical devices, and systems biology.

About SRI International
Innovations from SRI International have created new industries, billions of dollars of marketplace value, and lasting benefits to society—touching our lives every day. SRI, a nonprofit research and development institute based in Silicon Valley, brings its innovations to the marketplace through technology licensing, new products, and spin-off ventures. Government and business clients come to SRI for pioneering R&D and solutions in computing and communications, chemistry and materials, education, energy, health and pharmaceuticals, national defense, robotics, sensing, and more.

Visit SRI's website and Timeline of Innovation to learn more about SRI.


'/>"/>
SOURCE SRI International
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. UV Flu Technologies Expands Its International Footprint
2. Elsevier Supports International Crisis Aid Through Pillars of Hope Campaign
3. International Attendance for Networking and Education at Informex Beyond Manufacturing
4. Sundberg Kicks Off National Expansion With Openings of New Headquarters, Logistically Centric Mega Warehouses
5. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
6. Experts Launch the Alliance for Fertility Preservation at the International Society for Fertility Preservations 2nd World Congress
7. First Free-Standing International Mesothelioma Research Laboratory Opens in Los Angeles
8. Cord Blood America Announces Exclusive Agreement With National Childrens Leukemia Foundation to Store Stem Cells
9. PAREXEL International to Present at J.P. Morgan Healthcare Conference
10. DFH Pharma to Collaborate With National Cancer Institute to Develop Second-Generation HIV Maturation Inhibitor Drugs
11. Elsevier Launches Bilingual International Nursing Skill Training and Management Platform: NursingChina.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)...  Renova™ Therapeutics, a biotechnology company developing gene ... 2 diabetes, announced that it has obtained a ... vector developed in the laboratory of Professor ... The company plans to use this vector in ... "Early research has shown promise ...
(Date:12/8/2016)... ... December 08, 2016 , ... Opal Kelly, a ... device-to-computer interconnect using USB or PCI Express, announced the FOMD-ACV-A4, the company's first ... a small, thin, SODIMM-style module that fits a standard 204-pin SODIMM socket for ...
(Date:12/8/2016)... , Dec. 8, 2016  Anaconda BioMed S.L., ... development of the next generation neuro-thrombectomy system for the ... of Tudor G. Jovin, MD to join its Scientific ... as a strategic network of scientific and clinical experts ... development of the ANCD BRAIN ® to its ...
(Date:12/8/2016)... ... December 08, 2016 , ... Microbial genomics ... Awards. uBiome is one of just six company finalists in the Health & ... to uBiome, companies nominated as finalists in this year’s awards include Google, SpaceX, ...
Breaking Biology Technology:
(Date:11/21/2016)... , Nov. 21, 2016   Neurotechnology , ... recognition technologies, today announced that the MegaMatcher On ... was submitted for the NIST Minutiae Interoperability ... all the mandatory steps of the evaluation protocol. ... a continuing test of fingerprint templates used to ...
(Date:11/16/2016)... , Nov. 16, 2016 Sensory Inc ... and security for consumer electronics, and VeriTran ... and retail industry, today announced a global partnership ... way to authenticate users of mobile banking and ... TrulySecure™ software which requires no specialized biometric ...
(Date:11/14/2016)... , Nov. 14, 2016  Based ... identification market, Frost & Sullivan recognizes FST ... Sullivan Award for Visionary Innovation Leadership. FST ... the biometric identification market by pioneering In ... solution for instant, seamless, and non-invasive verification. ...
Breaking Biology News(10 mins):